Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 18/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.54 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10156286 | 1.00 | ADORA2A (0.54) | ADORA2AADORA3CCNE2CCNE1CDK2 | |
| SCHEMBL13246065 | 1.00 | ADORA2A (0.54) | ADORA2AADORA3CCNE2CCNE1CDK2 | |
| SCHEMBL10156029 | 0.97 | ADORA2A (0.53) | ADORA2AADORA3CCNE2CCNE1CDK2 | |
| SCHEMBL4124626 | 0.93 | ADORA2A (0.49) | ADORA2AADORA3CCNE2CCNE1CDK2 | |
| SCHEMBL4118723 | 0.93 | ADORA2A (0.49) | ADORA2AADORA3CCNE2CCNE1CDK2 | |
| SCHEMBL10195035 | 0.93 | ADORA2A (0.61) | ADORA2AADORA3CDK1CDK5 | |
| SCHEMBL10155736 | 0.93 | ADORA2A (0.61) | ADORA2AADORA3CDK1CDK5 | |
| SCHEMBL10156281 | 0.93 | ADORA2A (0.61) | ADORA2AADORA3CDK1CDK5 | |
| SCHEMBL4119779 | 0.93 | ADORA2A (0.54) | ADORA2AADORA3CCNE2CCNE1CDK2 | |
| SCHEMBL4119771 | 0.93 | ADORA2A (0.54) | ADORA2AADORA3CCNE2CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193164-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-8193164-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-20100190784-A1 | Organic Compounds | NOVARTIS AG | 2010-07-29 | — | — | US | disclosed |
| US-20100190784-A1 | Organic Compounds | NOVARTIS AG | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190784-A1 | Organic Compounds | CYP1B1, POLR2A, CYP1A1 | ADORA2A 1137/4885ADORA3 1044/4885CCNE2 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.